Anebulo Pharmaceuticals (FRA:214) Current Accrued Expense : €0.58 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Current Accrued Expense?

Anebulo Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2024 was €0.58 Mil.

Anebulo Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2023 (€0.14 Mil) to Dec. 2023 (€0.64 Mil) but then declined from Dec. 2023 (€0.64 Mil) to Mar. 2024 (€0.58 Mil).

Anebulo Pharmaceuticals's annual Current Accrued Expense increased from Jun. 2021 (€0.11 Mil) to Jun. 2022 (€0.13 Mil) and increased from Jun. 2022 (€0.13 Mil) to Jun. 2023 (€0.49 Mil).

Anebulo Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Anebulo Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Current Accrued Expense Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

0.02

0.11

0.13

0.49

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial										0.86	0.49	0.14	0.64	0.58

Anebulo Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Anebulo Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines